No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
50 (estimated)
Sponsor
IRCCS San Raffaele · Other
Who this trial is looking for
This trial is looking for patients who are experiencing cardiogenic shock or cardiac arrest and require a special heart-lung machine called VA-ECMO. Participants will receive cangrelor, a medication that helps prevent blood clots, in addition to their current treatment.
Are You a Good Fit for This Trial?
Must not be takingOral P2Y12-inhibitors
Rules you outStrokeTransient Ischaemic Attack
You may be able to join if
I am at least 18 years old
I have cardiogenic shock or cardiac arrest
I am undergoing a procedure to open heart arteries
I need VA-ECMO support
I have received a loading dose of aspirin or never taken blood thinners
I have provided written consent to participate
You may not be able to join if
I have uncontrolled bleeding
I have suspected bleeding in my brain
I have taken any oral blood thinners
I have a history of stroke or mini-strokes
I am allergic to cangrelor or its ingredients
I am pregnant
Summarized in plain language from this trial's official eligibility criteria.
The full criteria are further down this page — only the research team can
confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
The SURVIVE trial aims to test whether using an anti-thrombotic regimen involving cangrelor can reduce bleeding risk while maintaining effective antithrombotic effects in patients on VA-ECMO due to cardiogenic shock (CS)/ cardiac arrest (CA) who undergo percutaneous coronary intervention (PCI). The investigators plan to achieve this by starting cangrelor on top of systemic anticoagulation with biv…
The SURVIVE trial aims to test whether using an anti-thrombotic regimen involving cangrelor can reduce bleeding risk while maintaining effective antithrombotic effects in patients on VA-ECMO due to cardiogenic shock (CS)/ cardiac arrest (CA) who undergo percutaneous coronary intervention (PCI). The investigators plan to achieve this by starting cangrelor on top of systemic anticoagulation with bivalirudin at a low dose, regularly monitoring platelet function, and adjusting the dose based on the results of platelet function assay (Multiplate®) to guarantee effective platelet P2Y12 pathway inhibition to achieve optimal platelet inhibition. Platelet function assays will be performed at various time points throughout the treatment timeframe. Cangrelor will then be stopped at the end of VA-ECMO support, and patients will be transitioned to oral P2Y12- inhibitors as per clinical guidelines.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
* Male or female patients aged ≥18 years;
* ACS-related CS/CA patients undergoing PCI (either with or without stent implantation) and needing VA-ECMO support;
* Patients who received pre-hospital aspirin intravenous loading dose or patients naïve to any anti-thrombotic agent;
* …
Inclusion Criteria:
* Male or female patients aged ≥18 years;
* ACS-related CS/CA patients undergoing PCI (either with or without stent implantation) and needing VA-ECMO support;
* Patients who received pre-hospital aspirin intravenous loading dose or patients naïve to any anti-thrombotic agent;
* Written informed consent
Exclusion Criteria:
* Overt uncontrollable bleeding;
* Suspected intra-cranial haemorrhage;
* Patients who received any dose of any oral P2Y12-inhibitors;
* Patients with known history of stroke or Transient Ischaemic Attack (TIA);
* Patients with known hypersensitivity to the active substance (cangrelor) or to any of its excipients;
* Pregnancy.
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.
